"The FTC has twice sought to persuade the Supreme Court to consider 
cases challenging pay-for-delay agreements, but both cases were 
turned away.   ...  But society also has a strong interest in making 
sure that generic drugs become available as soon as legally 
appropriate.  ...  At this point, there's little to be gained, at 
least for consumers, from backroom deals made by interested corporate 
parties."

<http://www.latimes.com/news/opinion/editorials/la-ed-ftc5-2009feb05,0,5897259.story>http://www.latimes.com/news/opinion/editorials/la-ed-ftc5-2009feb05,0,5897259.story 




Powered by LSoft's LISTSERV(R) list management software